Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the phenylbenzimidazole class and features a 1,3,4‑oxadiazole‑2(3H)‑thione moiety. It is catalogued as an experimental drug with no approved medical indications or clinical trial data available. The compound has been studied in preclinical settings for its potential pharmacological properties but lacks detailed information on mechanism of action or therapeutic targets[1][7][9]. Its molecular formula is C16H12N4O2S and it has an average molecular weight of approximately 324.36 g/mol[2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione.